Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events
Deepak L. Bhatt(Mount Sinai Hospital), Robert A. Harrington(Clinical Research Institute), C. Michael Gibson(Baim Institute for Clinical Research), Philippe Généreux(Morristown Medical Center), Christian W. Hamm(Justus-Liebig-Universität Gießen), Kenneth W. Mahaffey(Cardiovascular Institute of the South), Simona Skerjanec(Doctors Company (United States)), Dominick J. Angiolillo(University of Florida), Peter W. Radke(Schön Klinik Neustadt), Gregg W. Stone(Cardiovascular Institute of the South), Dianne Gallup(Clinical Research Institute), Meredith Todd(Doctors Company (United States)), František Toušek(Nemocnice České Budějovice), Harvey D. White(University of Auckland), Tiepu Liu(Doctors Company (United States)), Sergio Leonardi(Policlinico San Matteo Fondazione), Matthew J. Price(Scripps Clinic), Brent McLaurin(AnMed Health), Jayne Prats(Doctors Company (United States)), Jeffrey Tauth(Ark Medical Center), Petr Widimský(Charles University), Ezio Bramucci(Policlinico San Matteo Fondazione), Douglas Spriggs, Philippe Gabríel Steg(Mount Sinai Hospital)
Cited by 825
Related Papers
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
|New England Journal of Medicine|2011|9.4k
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
|New England Journal of Medicine|2017|7.7k
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2009|7.1k
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation
|European Heart Journal|2012|6.8k
Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2007|6.7k